Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer

<div>Distribution of BCR risk score, time-dependent ROC curves at 1, 3, and 5 years and Kaplan-Meier survival curves between patients in low and high BCR risk groups in training set (a), internal validation set (b), and entire TCGA cohort (c).</div>

Disease Markers

fig2

Figure 2

Figure 2: Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer 

Figure 2 | Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer 